JMP Securities analyst Jason Butler lowered the firm’s price target on Cytokinetics to $106 from $110 and keeps an Outperform rating on the shares. Cytokinetics reported Q1 financial results and said that all key aficamten activities remain on track, the analyst tells investors in a research note. The firm looks forward to next week’s presentations of Phase 3 SEQUOIA-HCM results to reaffirm the best-in-class profile of the candidate.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Reports First Quarter 2024 Financial Results
- Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
- Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Cytokinetics to Hold Annual Meeting of Stockholders
- CYTK Earnings this Week: How Will it Perform?